Metsera Inc. (NASDAQ:MTSR) Given Average Recommendation of “Hold” by Brokerages

Metsera Inc. (NASDAQ:MTSR) has been given a consensus rating of “Hold” by the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $55.75.

Several equities analysts recently weighed in on MTSR shares. Cantor Fitzgerald restated an “overweight” rating on shares of Metsera in a research note on Wednesday, September 3rd. Wall Street Zen upgraded Metsera from a “sell” rating to a “hold” rating in a research report on Wednesday, October 1st. Bank of America lifted their target price on shares of Metsera from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Wells Fargo & Company cut Metsera from an “overweight” rating to an “equal weight” rating and set a $54.00 price target for the company. in a report on Tuesday, September 30th. Finally, Leerink Partnrs cut Metsera from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 24th.

Hedge Funds Weigh In On Metsera

Several large investors have recently bought and sold shares of the business. Legal & General Group Plc grew its position in shares of Metsera by 1.1% in the third quarter. Legal & General Group Plc now owns 23,491 shares of the company’s stock valued at $1,229,000 after purchasing an additional 245 shares during the last quarter. Osaic Holdings Inc. boosted its stake in Metsera by 45.5% in the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company’s stock worth $27,000 after buying an additional 296 shares during the last quarter. Swiss National Bank grew its holdings in Metsera by 1.5% in the third quarter. Swiss National Bank now owns 40,700 shares of the company’s stock valued at $2,130,000 after purchasing an additional 600 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Metsera by 100.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company’s stock worth $46,000 after buying an additional 800 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Metsera during the third quarter worth about $44,000.

Metsera Stock Performance

Metsera stock opened at $70.50 on Monday. The stock has a 50-day moving average of $62.33 and a two-hundred day moving average of $43.97. The stock has a market cap of $7.42 billion and a PE ratio of -11.16. Metsera has a one year low of $12.30 and a one year high of $83.86.

Metsera (NASDAQ:MTSR) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.55).

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.